Anti-CD154mAb is a powerful co-stimulation blockade agent that is efficacious in preventing rejection, even in xenogeneic settings. It has been used in the majority of successful long-term pig-to-non-human primate islet transplantation models. However, its clinical use was halted as a result of thromboembolic complications that were also observed in preclinical and clinical organ transplantation models. An anti-CD154mAb was administered to 14 streptozotocin-induced diabetic cynomolgus monkey recipients of porcine islets, some of which received the agent for many months. Monkeys were monitored for complications, and blood monitoring was carried out frequently. After euthanasia, multiple biopsies of all organs were examined for histological features of thromboembolism. Anti-CD154mAb prevented rejection of genetically engineered pig islets in all monkeys. No significant complications were attributable specifically to antiCD154mAb. There was no evidence of thromboembolism in multiple histological sections from all major organs, including the brain. Our data suggest that in diabetic monkeys with pig islet grafts, anti-CD154mAb would appear to be an effective and safe therapy, and is not associated with thromboembolic complications.
| INTRODUCTION
Co-stimulation blockade was developed to target (and block) communication along the secondary pathway required for T-cell activation, 1 and has proven to be a powerful form of immunosuppressive therapy, even in preclinical models of xenotransplantation where the T-cell response is generally considered to be stronger than after allotransplantation. 2 It is usually directed to block the CD28/B7 and/or CD40/ CD154 pathways. Historically, CTLA4-Ig is used to block the CD28/ B7 pathway and an anti-CD154 monoclonal antibody (mAb) or antiCD40mAb to block the CD40/CD154 pathway.
1
The combination of these agents successfully prevented kidney allograft rejection in a non-human primate (NHP) model. 3 AntiCD154mAb monotherapy worked well in monkeys with renal 4 or islet 5 allotransplants, whereas CTLA4-Ig monotherapy showed only modest ability to prolong similar allograft function. 6 In a 2000 study on the transplantation of porcine peripheral blood progenitor cells into baboons, anti-CD154mAb successfully prevented sensitization to the graft. 7 This success in a xenograft model led to anti-CD154mAb being widely used in xenotransplantation studies involving NHPs, 2 including those of islet xenotransplantation.
8-10
The broadly powerful immunotherapeutic effects of antiCD154mAb are likely derived through several mechanisms. It impacts (i) T cells by blocking the secondary signal and (ii) B-cell function through lack of T-cell help. It also acts (iii) by blocking soluble CD154 released by platelets, 11 and (iv) by its effect on vascular endothelial cells by modulating CD154-mediated adhesion molecules and cytokine receptors. 12, 13 Following promising results in animal models, anti-CD154mAb was tested in clinical trials. Phase 1 and phase 2 trials were conducted (by Biogen, Cambridge, MA, USA) from 1997 to 1999 in patients with immune thrombocytopenic purpura, systemic lupus erythematosus, factor VIII antibody syndrome, and in patients undergoing renal transplantation. These trials showed efficacy, but were halted when several patients suffered thromboembolic events. in patients with systemic lupus erythematosus, the agent proved safe but was not efficacious. 15 Clinical use of anti-CD154mAb was put on hold.
Thromboembolic events have also been reported in NHPs in association with use of anti-CD154mAb. [16] [17] [18] [19] [20] The mechanisms behind these secondary effects appear to involve the formation of immune complexes between anti-CD154mAb and CD154, with subsequent platelet activation via the IgG receptor FcγRIIA, thus triggering coagulation. 21 A role for the IgG receptor FcγRIIA on adjacent platelets was also proposed for increasing the risk of thrombosis. 22 Anti-CD154mAb may also affect arterial thrombi stabilization.
23
Heparin and other anticoagulants have shown efficacy in reducing anti-CD154mAb-mediated thromboembolism. [16] [17] [18] [19] 24 The last 10 years have brought forth several successful preclinical pig-to-NHP islet xenotransplantation studies, reviewed by Park CG et al., 25 including our own. 9,10 Successful models have been differentiated by characteristics of the pig islet donor while the studies were almost universal in using co-stimulation blockade immunosuppression, most frequently based on an anti-CD154mAb. 25 The aim of this study was to determine whether relatively prolonged administration (up to 1 year) of an anti-CD154mAb was associated with thromboembolic events in monkeys with porcine islet transplants.
| MATERIALS AND METHODS

| Porcine islet donors
Islets were harvested from wild-type (WT) pigs (n=2) (Wally Whippo, Enon Valley, PA, USA) or genetically engineered (GE) pigs with one or more modifications (see Table 1 for information on the genetics of donor pigs); α1,3-galactosyltransferase gene-knockout (GTKO, n=2), transgenic for hCD46 (n=5), three GE (GTKO, hCD46, hCD39, n=1), four GE (GTKO, hCD46, hCD39, hTFPI, n=2), or five GE (GTKO, hCD46, hCD39, hTFPI, CTLA4-Ig, n=2) pigs (all from Revivicor, Blacksburg, VA, USA). Table 2 . n/a, not measured; GE, genetically engineered; GTKO, α1,3-galactüsyltransferase gene knockout; hTFPI, human tissue factor pathway inhibitor; WT, wild type; 3-GE, GTKO/hCD46/hCD39; 4-GE, GTKO/hCD46/hTFPI/CTLA4-Ig; 5-GE, GTKO/hCD46/hCD39/hTFPI/CTLA4-Ig. *Monkeys 6, 8 received two transplants and two courses of ATG.
previously described. 10 The monkeys were 2-5 years of age and 
| Immunosuppressive and adjunctive therapy
The immunosuppressive (and adjunctive drug) regimen was based on anti-CD154mAb and is summarized in Table 2 . Anti-CD154mAbs
(ABI793 [Novartis Pharma, Basel, Switzerland; n=9] or chimeric h5c8
[NIH NHP Reagent Resource, Boston, MA, USA; n=5]) were used for induction, with the same antibody also being used for maintenance of immunosuppression. Dosage was modulated to maintain serum trough levels in the anticipated range. Trough levels were not measured in five monkeys which were, therefore, administered a dose proportionally higher than received by the other monkeys.
Apart from low-dose continuous heparin infusion to maintain i.v. catheter patency (Table 1) , the only antiplatelet/anticoagulant/ anti-inflammatory agent administered to the monkeys was aspirin (81 mg/d; Table 2 ).
| Monitoring
The monkeys were monitored clinically for signs of infection or thromboembolism. Daily records of the following signs were kept-mobility impairment, lack of coordination, hypotonic limbs, hemiplegia, respiratory dysfunction (shortness of breath), and diarrhea, in addition to lack of appetite and lack of interest in enrichment activities. Blood was collected at least monthly for complete blood counts and tests of renal and hepatic function (Presbyterian Hospital, University of Pittsburgh Medical Center). Blood glucose was monitored at least ×2 daily, and insulin was administered to maintain the blood glucose <200 mg/dL pretransplant and, as necessary afterward. The studies were designed for follow-ups of 3, 6, or 12 month, at which time monkeys were electively euthanized. 9, 10 Serum levels of porcine C-peptide were measured at intervals as an indicator of graft function. If undetectable, the recipient monkey was euthanized. Whole-blood trough levels of anti-CD154mAb were measured by competitive inhibition ELISA 26 in nine of the 14 monkeys. The activated clotting time (ACT) was measured using I-Stat (Abbott, Princeton, NJ, USA) while heparin was being administered.
| Necropsy and microscopic examination of major organs
After euthanasia, a full necropsy was performed in all monkeys. All major organs (brain, heart, intestine, kidney, liver, lung) were cut into 3 | RESULTS
| Clinical observations
Follow-up after islet transplantation ranged from 8 to 365 days with a mean of 163 days and a median of 125 days (Table 1) . Nine monkeys were followed for >3 months, five for >6 months, and three for Parameters such as white and red blood cell and platelet counts, as well as those of hepatic and renal function, did not show significant changes during the post-transplant phase in the study animals. 9,10 ACT levels were 127±25s (mean±SD, n=12) while heparin (and aspirin) was being administered.
There was no evidence of thromboembolic events in the monkeys regardless of whether they received a higher or lower dose of antiCD154mAb (Table 1) .
| Histopathology of major organs
At necropsy, no macroscopic evidence of abnormalities was seen.
Multiple H&E-stained sections from the major organs in all monkeys were examined: no microscopic features of thrombosis or embolism were detected. Figure 1 shows representative images from H&E-stained tissues of two recipients that were followed up for 1 year.
| DISCUSSION
Of the several groups that have reported relatively long-term successful pig islet transplantation in diabetic monkeys, 25 only one recorded any severe adverse events associated with anti-CD154mAb in recipient NHPs treated with the antibody, affecting eight of nine monkeys tested. 27 In that study, however, it was difficult to distinguish the specific side effects of anti-CD154mAb from those of other agents that were administered, for example, everolimus, which can also increase thrombotic events. 28 Previous studies, including relevant work by Cardona et al. 29 and Thompson et al. 30 with WT as well as GTKO neonatal islets, observed no adverse anti-CD154mAb-derived events. Although follow-up was for <1 year, this finding is significant in view of the fact that neonatal pig islets (that express galactose-α1,3-galactose [Gal]) are more thrombogenic than adult islets.
31
In our own preclinical studies of porcine islet xenotransplantation, an anti-CD154mAb-based immunosuppressive regimen has proved effective in maintaining islet graft function for at least 1 year and has been well tolerated and safe over relatively long periods of administration. 9, 10 We have employed both the ABI793 and h5c8 varieties of the mAb in cynomolgus monkey and baboon recipients of other porcine organs/tissues. We have reported thrombosis in pig artery patch 17 and organ 18 xenotransplantation models.
Our observations in the present study on the lack of adverse events are relevant in light of earlier reports of thromboembolism in both preclinical NHP studies 16, [18] [19] [20] and in clinical trials 14 that were halted because of the incidence of this complication. To note, none of those earlier preclinical and clinical studies involved islet cells.
In our present study, 14 monkeys were administered antiCD154mAb during follow-up, with 12 being followed for >45 days, Also of note, of three groups with the most sustained anti-CD154mAb treatment, 9,10,27 the only group to report severe events associated with its use was also the only one not to extend anticoagulant coverage beyond the transplant. 27 These observations suggest that extended administration of anticoagulants, even in relatively small doses, may be beneficial.
Is it possible that the genetic engineering of the porcine islets may have provided protection against thromboembolic events? The expression of hCD39 and/or human tissue factor pathway inhibitor (hTFPI) in some of the pig donor islet grafts may have protected against thromboembolism. 10 The addition of CTLA4-Ig or hCD46, or the deletion of Gal in pig aortic endothelial cells would not be predicted to have had a major impact on thrombosis. 33 This is supported by the absence of thromboembolic complications in recipients of WT donor pig islets in our study and, after much longer follow-up, in the study by Shin et al. 32 Importantly, in combinations of five different GE donor islets along with two types of anti-CD154mAbs studied (Table 1) , the lack of thromboembolic events was general. Based on our data, the specific genetic manipulation does not appear to influence the occurrence of thromboembolic events either negatively or positively. We suggest that the absence of thromboembolism irrespective of the genetic nature of the islet-source pig or of the immunosuppressive regimen strengthens our conclusion that antiCD154mAb was not thrombogenic under the circumstances of these experiments.
Although alternative co-stimulation blockade agents have beenor are being-developed, our experience and that of others 32 suggests that any anti-CD154mAb, when given as monotherapy (or combined with other less potent agents), is more potent than others, for example, CTLA4-Ig (abatacept and belatacept) and anti-CD40mAb, even though the results using this latter agent have been very encouraging following the xenotransplantation of solid pig organs. 34, 35 Because of their undoubted efficacy, attempts are being made to develop an antiCD154mAb that successfully blocks the CD40/CD154 pathway, but does not activate platelets. 
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